Actuate Therapeutics, INC Form 4 insider transactions

Director Todd Thomson was granted 15,000 stock options in Actuate Therapeutics, Inc. with an exercise price of $2.42.

Director Roger Sawhney was granted 15,000 stock options in Actuate Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Amy L. Ronneberg was granted 15,000 stock options in Actuate Therapeutics, Inc. as disclosed in a recent SEC Form 4 filing.

Director Jason A. Keyes was granted 15,000 stock options in Actuate Therapeutics, Inc. as part of a standard equity incentive.

Director Martin H. Huber Jr. was granted 15,000 stock options in Actuate Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Aaron G.L. Fletcher was granted 15,000 stock options in Actuate Therapeutics, Inc. as part of a standard equity compensation arrangement.

ACTUATE THERAPEUTICS, INC. President, CEO, and Director Daniel M. Schmitt was granted 237,000 employee stock options with an exercise price of $2.49.

Actuate Therapeutics' Chief Operating Officer, Andrew Paul Mazar, received a grant of 105,000 employee stock options with an exercise price of $2.49, vesting over four years.

ACTUATE THERAPEUTICS' Chief Financial Officer, Paul J Lytle, was granted 105,000 employee stock options with an exercise price of $2.49.

ACTUATE THERAPEUTICS CEO Daniel M. Schmitt reported the vesting and settlement of 272,055 restricted stock units, with 121,874 shares withheld for taxes.

Actuate Therapeutics director and 10% owner Todd S. Thomson sold 280,000 shares of common stock at $5.80 per share through a pre-arranged trading plan.

Bios Equity COF, LP and affiliated entities have increased their beneficial ownership in Actuate Therapeutics, Inc. through a private placement of common stock and warrants.

A group of entities affiliated with Director and 10% Owner Leslie W. Kreis, including Bios 2024 Co-Invest, LP, acquired additional common stock and warrants in Actuate Therapeutics, Inc. through a private placement.

Aaron G.L. Fletcher, a Director and 10% Owner of Actuate Therapeutics, Inc., along with affiliated Bios entities, acquired 71,428 shares of common stock and warrants in a private placement, increasing their beneficial ownership to over 10 million shares.

Actuate Therapeutics, Inc. disclosed that Director and 10% Owner Todd S. Thomson was granted 15,000 stock options with an exercise price of $10.1, vesting fully on the anniversary of the grant date.

Roger Sawhney, a Director at Actuate Therapeutics, Inc. (ACTU), was granted 15,000 stock options with an exercise price of $10.10 per share, vesting fully on the anniversary of the grant date.

Actuate Therapeutics, Inc. Director Dan Zabrowski was granted 15,000 stock options with an exercise price of $10.1, vesting on the anniversary of the grant date.

Aaron G.L. Fletcher, a Director and 10% owner of Actuate Therapeutics, Inc., was granted 15,000 stock options with an exercise price of $10.10, vesting on the anniversary of the grant date.

Actuate Therapeutics, Inc. disclosed in a recent SEC Form 4 filing that Director Jason A. Keyes was granted 15,000 stock options with an exercise price of $10.10 per share, vesting fully on the anniversary of the grant date.

Actuate Therapeutics, Inc. Director Amy L. Ronneberg was granted 15,000 stock options with an exercise price of $10.10, as disclosed in a recent SEC Form 4 filing.

Daniel Schmitt, CEO and Director of Actuate Therapeutics, reports the acquisition of employee stock options.

Andrew Paul Mazar, Chief Operating Officer of Actuate Therapeutics, acquired stock options on April 1, 2025, according to a Form 4 filing with the SEC.

Paul Lytle, CFO of Actuate Therapeutics, reports the acquisition of employee stock options.

Bios Equity COF, LP files an amendment to its Form 4, correcting the price reported in a previous filing related to transactions in Actuate Therapeutics, Inc. (ACTU) common stock following the company's IPO.

An amended SEC Form 4 filing reveals a correction to the price reported in a previous filing related to warrant exercises following Actuate Therapeutics' IPO, with no new transactions reported.

Leslie Kreis, a director and 10% owner of Actuate Therapeutics, files an amended Form 4 to correct the stock price reported in a previous filing related to warrant exercises following the company's IPO.

Todd Thomson, a director and significant owner of Actuate Therapeutics, and related Kairos Funds, reported changes in beneficial ownership following the company's IPO, including conversions of preferred stock and warrant exercises.

Bios Equity COF, LP, along with related entities and individuals, reports beneficial ownership of Actuate Therapeutics, Inc. common stock as of August 12, 2024.

Following Actuate Therapeutics' IPO, Bios Equity and related entities report changes in beneficial ownership, including conversions of preferred stock and cashless exercises of warrants.

Aaron G.L. Fletcher, a director and 10% owner of Actuate Therapeutics, along with related entities under BIOS Equity Partners, reported changes in beneficial ownership of the company's common stock.